Granted Patent
B2
US 12,304,933 · App. 17/282,872 · Granted May 20, 2025
Disease treatment drug based on mesenchymal-stem-cell mobilization
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present inventors identified many nuclear proteins contained in the extract of skin tissue by mass spectrometry, randomly selected multiple partial amino acid sequences of the nuclear proteins, chemically synthesized peptides consisting of the partial amino acid sequences, and examined their activity of mobilizing mesenchymal stem cells. As a result, it was found that these multiple peptides show the activity of mobilizing mesenchymal stem cells into peripheral blood, even though their amino acid sequences are completely different from each other. The inventors also found that fragment peptides of the nuclear proteins have therapeutic effects on diseases characterized by inflammation and abnormalities of the immune system (e.g., inflammatory bowel disease and psoriasis). Based on these findings, a new regenerative medicine technology that can overcome the problems of cell transplantation therapy is provided.
Claims (5)
1. A method for mobilizing mesenchymal stem cells to peripheral blood, comprising administering to a subject an effective amount of a peptide consisting of the amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 35 to 56, wherein the peptide consists of a fragment of a nuclear protein and has activity of mobilizing mesenchymal stem cells to peripheral blood.
2. The method of claim 1 , wherein the peptide consists of the amino acid sequence selected from the group consisting of SEQ ID NOs: 35 to 56.
3. The method of claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 36.
4. The method of claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 47.
5. A method for mobilizing mesenchymal stem cells to peripheral blood, comprising administering to a subject an effective amount of a peptide consisting of the amino acid sequence that is at least 95% identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 35 to 56; wherein the peptide consists of a fragment of a nuclear protein and has activity of mobilizing mesenchymal stem cells to peripheral blood; and wherein the nuclear protein is (1) basic transcription factor 3 (BTF3) protein, (2) suppressor of Ty 16 Homolog (SUPT16H) protein, (3) Y-box binding protein 1 (YBX1) protein, (4) nucleophosmin 1 (NPM1) protein, (5) proliferation-associated protein 2G4 (PA2G4) protein, (6) prefoldin subunit 5 (PFDN5) protein, (7) proteasome 26S subunit, ATPase 3 (PSMC3) protein, or (8) heterogeneous nuclear ribonucleoprotein K (HNRNPK) protein.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 25, 2021
From: YAMAZAKI, TAKEHIKO
To: STEMRIM INC.
Reel/Frame 056668/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 25, 2021
From: TAMAI, KATSUTO; SHIMBO, TAKASHI
To: OSAKA UNIVERSITY
Reel/Frame 056669/0105 →
Priority Claims (1)
JP 2018-190089
· Oct 5, 2018
· national
Continuity (1)
References Cited (400)
US 3896810A
· Akiyama
· 1975
[cited by applicant]
US 4732155A
· Zetter et al.
· 1988
[cited by applicant]
US 5133755A
· Brekke
· 1992
[cited by applicant]
US 5661127A
· Bhatnagar et al.
· 1997
[cited by applicant]
US 5760261A
· Guttag
· 1998
[cited by applicant]
US 5851986A
· Takada et al.
· 1998
[cited by applicant]
US 5902799A
· Herrmann et al.
· 1999
[cited by applicant]
US 6723319B1
· Ito et al.
· 2004
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7220723B2
· Tracey et al.
· 2007
[cited by applicant]
US 7288250B2
· Newman et al.
· 2007
[cited by applicant]
US 7446100B2
· Pilarski
· 2008
[cited by applicant]
US 7470538B2
· Laughlin et al.
· 2008
[cited by applicant]
US 7585504B2
· Wu et al.
· 2009
[cited by applicant]
US 7632802B2
· Tessier et al.
· 2009
[cited by applicant]
US 7749959B2
· Tracey et al.
· 2010
[cited by applicant]
US 7829097B2
· Tsung et al.
· 2010
[cited by applicant]
US 7833975B2
· Okazawa
· 2010
[cited by applicant]
US 7939057B2
· Battista et al.
· 2011
[cited by applicant]
US 8114668B2
· Stolen et al.
· 2012
[cited by applicant]
US 8119121B2
· Fraser et al.
· 2012
[cited by applicant]
US 8551470B2
· Son et al.
· 2013
[cited by applicant]
US 8673580B2
· Tamai et al.
· 2014
[cited by applicant]
US 9623078B2
· Tamai et al.
· 2017
[cited by applicant]
US 9688733B2
· Tamai et al.
· 2017
[cited by applicant]
US 9919010B2
· Tamai et al.
· 2018
[cited by applicant]
US 20030003482A1
· Halle et al.
· 2003
[cited by applicant]
US 20030060410A1
· Tracey et al.
· 2003
[cited by applicant]
US 20040031072A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20040156851A1
· Newman
· 2004
[cited by applicant]
US 20040191246A1
· Connelly et al.
· 2004
[cited by applicant]
US 20040242481A1
· Bianchi et al.
· 2004
[cited by applicant]
US 20040249448A1
· Gault
· 2004
[cited by applicant]
US 20040265971A1
· Sato et al.
· 2004
[cited by applicant]
US 20050014255A1
· Tang et al.
· 2005
[cited by applicant]
US 20050101564A1
· Pilarski
· 2005
[cited by applicant]
US 20060003312A1
· Blau et al.
· 2006
[cited by applicant]
US 20060035851A1
· Bianchi et al.
· 2006
[cited by applicant]
US 20060039896A1
· Kleinsek et al.
· 2006
[cited by applicant]
US 20060069064A1
· Khaldoyanidi
· 2006
[cited by applicant]
US 20060111287A1
· Bianchi
· 2006
[cited by applicant]
US 20060183667A1
· Jonassen et al.
· 2006
[cited by applicant]
US 20070154529A1
· Bullerdiek
· 2007
[cited by applicant]
US 20070238663A1
· Capogrossi et al.
· 2007
[cited by applicant]
US 20090062187A1
· Bianchi et al.
· 2009
[cited by applicant]
US 20090202500A1
· Tamai et al.
· 2009
[cited by applicant]
US 20100040608A1
· Wahren-Herlenius et al.
· 2010
[cited by applicant]
US 20100280493A1
· Nayak
· 2010
[cited by applicant]
US 20110097309A1
· Tamai et al.
· 2011
[cited by applicant]
US 20120237504A1
· Brooks et al.
· 2012
[cited by applicant]
US 20200038486A1
· Tamai et al.
· 2020
[cited by applicant]
US 20200369736A1
· Tamai et al.
· 2020
[cited by applicant]
US 20210024594A1
· Tamai et al.
· 2021
[cited by applicant]
US 20210163552A1
· Nihashi et al.
· 2021
[cited by applicant]
US 20220009976A1
· Tamai et al.
· 2022
[cited by applicant]
US 20230212241A1
· Tamai et al.
· 2023
[cited by applicant]
US 20230241159A1
· Tamai et al.
· 2023
[cited by applicant]
AU 2003228099A1
· 2004
[cited by applicant]
AU 2004203732A1
· 2004
[cited by applicant]
AU 2007315073A1
· 2008
[cited by applicant]
AU 2012248676A1
· 2013
[cited by applicant]
CA 2325226A1
· 2001
[cited by applicant]
CA 2512512A1
· 2004
[cited by applicant]
CA 2636788A1
· 2008
[cited by applicant]
CN 1193092C
· 2005
[cited by applicant]
CN 1671742A
· 2005
[cited by applicant]
CN 1878793A
· 2006
[cited by applicant]
CN 101132811A
· 2008
[cited by applicant]
CN 101291955A
· 2008
[cited by applicant]
CN 100447154C
· 2008
[cited by applicant]
CN 101366728A
· 2009
[cited by applicant]
CN 101374538A
· 2009
[cited by applicant]
CN 101528266A
· 2009
[cited by applicant]
CN 101641372A
· 2010
[cited by applicant]
CN 102076350A
· 2011
[cited by applicant]
CN 102247392A
· 2011
[cited by applicant]
CN 102443064A
· 2012
[cited by applicant]
CN 103687946A
· 2014
[cited by applicant]
CN 102711777B
· 2015
[cited by applicant]
CN 104884076A
· 2015
[cited by applicant]
CN 1049555470A
· 2015
[cited by applicant]
CN 105026553A
· 2015
[cited by applicant]
CN 107188948A
· 2017
[cited by applicant]
CN 110494154A
· 2019
[cited by applicant]
EP 1114862A2
· 2001
[cited by applicant]
EP 1459759A1
· 2004
[cited by applicant]
EP 0791601B1
· 2005
[cited by applicant]
EP 2039367A1
· 2009
[cited by applicant]
EP 2055308A1
· 2009
[cited by applicant]
EP 2284255A1
· 2011
[cited by applicant]
EP 2301559A1
· 2011
[cited by applicant]
EP 2301560A1
· 2011
[cited by applicant]
EP 2601971A1
· 2013
[cited by applicant]
EP 2703487A1
· 2014
[cited by applicant]
EP 2913059A1
· 2015
[cited by applicant]
EP 2913058B1
· 2017
[cited by applicant]
EP 2494977B1
· 2018
[cited by applicant]
EP 3556378A1
· 2019
[cited by applicant]
EP 3358011B1
· 2020
[cited by applicant]
EP 3719117A1
· 2020
[cited by applicant]
EP 3750553A1
· 2020
[cited by applicant]
JP 3018313B2
· 2000
[cited by applicant]
JP 2003505506A
· 2003
[cited by applicant]
JP 3421741B2
· 2003
[cited by applicant]
JP 2005508913A
· 2005
[cited by applicant]
JP 2005512507A
· 2005
[cited by applicant]
JP 2005537253A
· 2005
[cited by applicant]
JP 2006510619A
· 2006
[cited by applicant]
JP 2006517537A
· 2006
[cited by applicant]
JP 2006523085A
· 2006
[cited by applicant]
JP 2008507505A
· 2008
[cited by applicant]
JP 2008511300A
· 2008
[cited by applicant]
JP 2010503630A
· 2010
[cited by applicant]
JP 4982739B2
· 2012
[cited by applicant]
JP 5134772B2
· 2013
[cited by applicant]
JP 5814549B2
· 2015
[cited by applicant]
KR 1020050054907A
· 2005
[cited by applicant]
KR 20090078304A
· 2009
[cited by applicant]
KR 101448800B1
· 2014
[cited by applicant]
KR 1020150103660A
· 2015
[cited by applicant]
KR 101636139B1
· 2016
[cited by applicant]
RU 2005102593A
· 2005
[cited by applicant]
RU 2410125C2
· 2011
[cited by applicant]
RU 2010148785A
· 2012
[cited by applicant]
RU 2599448C2
· 2016
[cited by applicant]
WO 0108683A1
· 2001
[cited by applicant]
WO 0234292A1
· 2002
[cited by applicant]
WO 02074337A1
· 2002
[cited by applicant]
WO 02088181A2
· 2002
[cited by applicant]
WO 02092004A2
· 2002
[cited by applicant]
WO 03026691A2
· 2003
[cited by applicant]
WO 03043651A1
· 2003
[cited by applicant]
WO 2004004763A2
· 2004
[cited by applicant]
WO 2004004770A1
· 2004
[cited by applicant]
WO 2004044001A1
· 2004
[cited by applicant]
WO 2004046345A2
· 2004
[cited by applicant]
WO 2004061456A2
· 2004
[cited by applicant]
WO 2005025604A2
· 2005
[cited by applicant]
WO 2005074984A1
· 2005
[cited by applicant]
WO 2005087797A1
· 2005
[cited by applicant]
WO 2006008779A1
· 2006
[cited by applicant]
WO 2006010628A1
· 2006
[cited by applicant]
WO 2006024547A2
· 2006
[cited by applicant]
WO 2006047820A1
· 2006
[cited by applicant]
WO 2006077614A1
· 2006
[cited by applicant]
WO 2006080434A1
· 2006
[cited by applicant]
WO 2006100651A1
· 2006
[cited by applicant]
WO 2006114805A2
· 2006
[cited by applicant]
WO 2007015546A1
· 2007
[cited by applicant]
WO 2007031100A1
· 2007
[cited by applicant]
WO 2007061762A2
· 2007
[cited by applicant]
WO 2007076200A2
· 2007
[cited by applicant]
WO 2007130725A2
· 2007
[cited by applicant]
WO 2008018641A1
· 2008
[cited by applicant]
WO 2008031612A1
· 2008
[cited by applicant]
WO 2008053892A1
· 2008
[cited by applicant]
WO 2008104090A1
· 2008
[cited by applicant]
WO 2008155659A2
· 2008
[cited by applicant]
WO 2009133939A1
· 2009
[cited by applicant]
WO 2009133940A1
· 2009
[cited by applicant]
WO 2009133943A1
· 2009
[cited by applicant]
WO 2011046570A1
· 2011
[cited by applicant]
WO 2011052668A1
· 2011
[cited by applicant]
WO 2012147470A1
· 2012
[cited by applicant]
WO 2014065347A1
· 2014
[cited by applicant]
WO 2014065348A1
· 2014
[cited by applicant]
WO 2014191364A1
· 2014
[cited by applicant]
WO 2016184795A1
· 2016
[cited by applicant]
WO 2016185476A1
· 2016
[cited by applicant]
WO 2018139562A1
· 2018
[cited by applicant]
WO 2018186480A1
· 2018
[cited by applicant]
WO 2018199107A1
· 2018
[cited by applicant]
WO 2019107530A1
· 2019
[cited by applicant]
WO 2019107566A1
· 2019
[cited by applicant]
WO 2019156137A1
· 2019
[cited by applicant]
WO 2020071520A1
· 2020
[cited by applicant]
WO 2020158924A1
· 2020
[cited by applicant]
WO 2021201260A1
· 2021
[cited by applicant]
Shi et al, Nucleocapsid Interacts with NPM1 and Protects it from Proteolytic Cleavage, Enhancing Cell Survival, and is Involved in PEDV Growth, Scientific Reports, 2017, pp. 1-16.
[cited by examiner]
Ko et al, SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC, Redox Biology, 2019, 24, pp. 1-10.
[cited by examiner]
Drumm et al, Genetic Variation and Clinical Heterogeneity in Cystic Fibrosis, Annu. Rev. Pathol. Mech. Dis., 2012, 7, pp. 267-282.
[cited by examiner]
Yampolsky et al, The Exchangeability of Amino Acids in Proteins, Genetics, 2005, 170, pp. 1459-1472.
[cited by examiner]
De Meyer et al, Extracellular Chromatin Is an Important Mediator of Ischemic Stroke in Mice, Arterioscler Thromb Vasc Biol, 2012, 32, pp. 1884-1891.
[cited by examiner]
SPT16 (D7I2K) Rabbit Monoclonal Antibody, from https://www.cellsignal.com/products/primary-antibodies/spt16-d7i2k-rabbit-mab/12191?N=572536551+4294956287&Nrpp=100&No=%7Boffset%7D&fromPage=plp, pp. 1-5, accessed Nov. 1, …
[cited by examiner]
Kolundzic et al, FACT Sets a Barrier for Cell Fate Reprogramming in Caenorhabditis elegans and Human Cells, Developmental Cell, 2018, 46, pp. 611-626.
[cited by examiner]
Leenaars et al, Critical Steps in the Production of Polyclonal and Monoclonal Antibodies: Evaluation and Recommendations, ILAR Journal, 2005, 46, pp. 269-279.
[cited by examiner]
Li, Z. et al., “Heat-Shock Proteins,” Current Protocols in Immunology, 2003, Supplement 58, A.IT.1-A.IT.6.
[cited by applicant]
Li, Y. et al., “Advancement of Human Multiply, Sex health and Reproductive Medical Science,” Peking University Medical Press, Mar. 2007, 1st Edition, pp. 270-271.
[cited by applicant]
Li, L., et al., “Emerging Role of HMGB 1 in Fibrotic Diseases.” Journal of Cellular and Molecular Medicine, 2014, 18(12): 2331-2339.
[cited by applicant]
Limana, F. et al., “Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation,” Circulation Research, 2005, 97(8): e7…
[cited by applicant]
Limana, F., et al., “HMGB1 Attenuates Cardiac Remodelling in the Failing Heart via Enhanced Cardiac Regeneration and miR-206-Mediated Inhibition of TIMP-3.” PLoS One, 2011, 6(6): e19845, pp. 1-11.
[cited by applicant]
Lin, S. et al., “The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells.” Experimental Cell Research, 2008, 314(17): 3107-3117.
[cited by applicant]
Liotta, F. et al., “Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling.” Stem Cells, 2008, 26(1): …
[cited by applicant]
Liu, K.et al., “Human Placental Extract Stimulates Liver Regeneration in Rats,” Biological and Pharmaceutical Bulletin, 1998, 21(1): 44-49.
[cited by applicant]
Lonza BenchGuides_Poietics hMSC Human Mesenchymal Stem Cells and Media (Document # TS-PT-212-7 Apr. 2008), 2008, Walkersville, MD, USA.
[cited by applicant]
Lund, L., et al., “The Registry of the International Society for Heart and Lung Transplantation: Thirty-Third Adult Heart Transplantation Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant.” The Jou…
[cited by applicant]
Mansbridge, J. et al., “Skin Tissue Engineering,” J. Biomater, Sci. Polymer, Ed., Aug. 1, 2008, 19(8): 955-968.
[cited by applicant]
Maron, B.J., et al., “Contemporary Definitions and Classification of the Cardiomyopathies—An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Com…
[cited by applicant]
Martin-Murphy, B.V. et al., “The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice,” Toxicol Lett, Feb. 2010, 192(3): 1-20.
[cited by applicant]
Maruyama, I., “Inflammation and HMGB1/RAGE system,” Kekkan Igaku, 2005, 6(5): 519-525 (English translation attached).
[cited by applicant]
Matsumoto, K., et al., “Up-Regulation of Hepatocyte Growth Factor Gene Expression by Inerleukin-1 in Human Skin Fibrosis,” Biochemical and Biophysical Research Communications, 1992, 188(1): 235-243.
[cited by applicant]
Meng, E. et al., “HMGB1 induces migration of human bone marrow-derived mesenchymal stem cells,” Bulletin of the Academy of Military Medical Sciences, 2006, 30(3): 213-216 (English translation attached).
[cited by applicant]
Meng, E. et al., “High Mobility Group Box 1 Protein Inhibits the Proliferation of Human Mesenchymal Stem Cells and Promotes Their Migration and Differentiation along Osteoblastic Pathway,” Stem Cells and Development, 20…
[cited by applicant]
Merenmies, J. et al., “30-kDa Heparin-binding Protein of Brain (Amphoterin) Involved in Neurite Outgrowth,” Journal of Biological Chemistry 1991, 266(25): 16722-16729.
[cited by applicant]
Mistry, A.R. et al., “Recombinant HMG1 Protein Produced in Pichia pastoris: A Nonviral Gene Delivery Agent,” Biotechniques, 1997, 22(4): 718-729.
[cited by applicant]
Mori, T. et al., “Stem Cells/ES cells—Mesenchymal Stem Cells—Human Bone Marrow Derived Mesenchymal Stem Cells,” Saisei Iryou—Regenerative Medicine, 2005, 4(3): 421-429, 351.
[cited by applicant]
Morosetti, R. et al., “MyoD expression restores defective myogenic differentiation of human mesoangioblasts from Inclusion-body myositis muscle,” PNAS, Nov. 7, 2006, 103(45): 16995-17000.
[cited by applicant]
Mouse care guidance from the Institutional Animal Care and Use Committee at University of California, San Francisco; iacuc.ucsf.edu/Policies/BloodCollectionMice.doc; accessed May 15, 2014.
[cited by applicant]
Muhamed, J. et al., “Phenotypic Modulation of Cell Types around Implanted Polyethylene Terephthalate Fabric in Rabbit Muscle.” Toxicologic Pathology, 2013, 41: 497-507.
[cited by applicant]
Muhammad, S. et al., “The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage.” The Journal of Neuroscience, Nov. 12, 2008, 28(46): 12023-12031.
[cited by applicant]
Müller, S. et al., “The double life of HMGB1 chromatin protein: architectural factor and extracellular signal,” EMBO Journal, 2001, 20(16): 4337-4340.
[cited by applicant]
Musumeci, D., et al., “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.” Pharmacology & Therapeutics, 2014, 141: 347-357.
[cited by applicant]
Nakajima et al., “Dynamics and Role of High Mobility Group Box-1 (HMGB-1) in Injured Spinal Cord,” Nihon Seikei Geka Gakkai Zasshi (J. Jpn. Orthop. Assoc.), 2010, 84(8): S1050.
[cited by applicant]
Nakamura, K. et al., “p38 Mitogen-Activated Protein Kinase Functionally Contributes to Chondrogenesis Induced by Growth/Differentiation Factor-5 in ATDC5 Cells,” Experimental Cell Research, 1999, 250(2): 351-363.
[cited by applicant]
Nakanishi, S., et al., “Membrane Potential-Regulated Ca2+ Signalling in Development and Maturation of Mammalian Cerebellar Granule Cells.” J. Physiol., 2006, 575(2): 389-395.
[cited by applicant]
Narumi, T., et al., “High-Mobility Group Box 1-Mediated Heat Shock Protein Beta 1 Expression Attenuates Mitochondrial Dysfunction and Apoptosis.” Journal of Molecular and Cellular Cardiology, 2015, 82: 1-12.
[cited by applicant]
Narumi, T., et al., “High-mobility Group Box 1 Attenuates Mitochondrial Dysfunction and Apoptosis via Heat Shock Protein Beta 1 Induction in Doxorubicin-induced Cardiomyopathy.” Bulletin of Yamagata University (Medical …
[cited by applicant]
NCBI, “Old myocardial infarction.” MedGen UID: 57612, retrieved from internet Jan. 19, 2022, <https://www.ncbi.nlm.nih.gov/medgen/57612>.
[cited by applicant]
Nickoloff, B. J., et al., “Recent Insights into the Immunopathogenesis of Psoriasis Provide new Therapeutic Opportunities.” J. Clin. Invest., 2004, 113(12): 1664-1675.
[cited by applicant]
NPM_Human, Accession No. P06748, accessed Jan. 19, 2022.
[cited by applicant]
O'Callaghan, A., et al., “HMGB1 as a Key Mediator of Tissue Response to Injury: Roles in Inflammation and Tissue Repair.” European Surgery, 2006, 38: 283-292.
[cited by applicant]
Opitz, C.E. et al., “Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2, 3-dioxygenase-1 via Interferon-β and Protein Ki…
[cited by applicant]
Otsuru, S. et al., “BMP-2 mobilizes robust bone marrow mesenchymal progenitor cells to the circulating blood in pone regeneration,” The 28th Meeting of the Molecular Biology Society of Japan, 2005, 733(3P-1012) (transla…
[cited by applicant]
Ozaki, Y. et al., “Comprehensive Analysis of Chemotactic Factors for Bone Marrow Mesenchymal Stem Cells,” Stem Cells and Development, 2007, 16(1): 119-129.
[cited by applicant]
PA2G4_Human, Accession No. Q9UQ80, Apr. 2001.
[cited by applicant]
Palumbo, R. et al., “Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation,” The Journal of Cell Biology, 2004, 164(3): 441-449.
[cited by applicant]
Palumbo, R. et al., “High mobility group box 1 protein, a cue for stem cell recruitment,” Biochemical Pharmacology, 2004, 68(6): 1165-1170.
[cited by applicant]
Palumbo, R. et al., “Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation,” Journal of Cell Biology, 2007, 179(1): 33-40.
[cited by applicant]
Pandya, N.M., et al., “Angiogenesis—A New Target for Future Therapy.” Vascular Pharmacology, 2006, 44: 265-274.
[cited by applicant]
Panepucci, R.A. et al., “Abstract # 4427: Comparison of Gene Expression of Mesenchymal Stem Cells from the Umbilical Cord and from the Bone Marrow,” Blood, Nov. 2003, 16(102): Abstract.
[cited by applicant]
Panepucci, R. A. et al., “Comparison of Gene Expression of Umbilical Cord Vein and Bone Marrow-Derived Mesenchymal Stem Cells.” Stem Cells, Dec. 2004, 22(7): 1263-1278.
[cited by applicant]
Pankov, R. et al., Fibronectin at a glance, J. Cell Sci., Oct. 2002, 115(20): 3861-3863.
[cited by applicant]
Park, J., et al., “Involvement of Toll-Like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein.” Journal of Biological Chemistry, 2004, 279(9): 7370-7377.
[cited by applicant]
Paul, S.R. et al., “Stromal Cell-Associated Hematopoiesis: Immortalization and Characterization of a Primate Bone Marrow-Derived Stromal Cell Line,” Blood, 1991, 77(8): 1723-1733.
[cited by applicant]
Pevsner-Fischer, M. et al., “Toll-like receptors and their ligands control mesenchymal stem cell functions,” Blood, 2007, 109(4): 1422-1432.
[cited by applicant]
PFD5_Human, Accession No. Q99471, Nov. 1997.
[cited by applicant]
Telusma, G. et al., “Dendritic cell activating peptides induce distinct cytokine profiles,” International Immunology, 2006, 18(11): 1563-1573.
[cited by applicant]
Teoh, N., et al., “Low-Dose TNF-Alpha Protects Against Hepatic Ischemia-Reperfusion Injury In Mice: Implications for Preconditioning.” Hepatology, 2003, 37(1): 118-128.
[cited by applicant]
Thorey, I.S. et al., “The Ca2+-binding Proteins S100A8 and S100A9 Are Encoded by Novel Injury-regulated Genes*,” Journal of Biological Chemistry, 2001, 276(38): 35818-35825.
[cited by applicant]
Tokuriki, N., et al., “Stability Effects of Mutations and Protein Evolvability.” Current Opinion in Structural Biology, 2009, 19: 596-604.
[cited by applicant]
Tsung, A., et al., “Hepatic Ischemia/Reperfusion Injury Involves Functional TLR4 Signaling in Nonparenchymal Cells.” The Journal of Immunology, 2005, 175(11): 7661-7668.
[cited by applicant]
Türker, S. et al., “Nasal route and drug delivery systems,” Pharmacy World and Science, 2004, 26: 137-142.
[cited by applicant]
Uchida et al., “Nihon Seikei Geka Gakkai Zasshi,” The Journal of Japanese Orthopaedic Surgical Society, 2005, 79(8): S832, 1-P6-6. (English translation attached, titled “The chemotactic activity of PDGF-bb BMP-2, and FG…
[cited by applicant]
Ueta, M., et al., “Intracellularly Expressed TLR2s and TLR4s Contribution to an Immunosilent Environment at the Ocular Mucosal Epithelium.” The Journal of Immunology, 2004, 173(5): 3337-3347.
[cited by applicant]
Ulloa, L. et al., “High-mobility group box 1 (HMGB1) protein: Friend and foe,” Cytokine & Growth Factor Reviews, 2006, 17: 189-201.
[cited by applicant]
Uronen-Hansson, H., et al., “Toll-like Receptor 2 (TLR2) and TLR4 are Present Inside Human Dendritic Cells, Associated with Microtubules and the Golgi Apparatus but are not Detectable on the Cell Surface: Integrity of M…
[cited by applicant]
User Manual for StemCell Technologies, “Enumeration, Expansion, and Differentiation of Human Mesenchymal Progenitor Cells Using MesenCult.” StemCell Technologies, Oct. 2007, Version 2.2.0.
[cited by applicant]
Vandal, K. et al., “Blockade of S100A8 and S100A9 Suppresses Neutrophil Migration in Response to Lipopolysaccharide.” The Journal of Immunology, Sep. 1, 2003, 171(5): 2602-2609.
[cited by applicant]
Venereau, E. et al., “Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.” The Journal of Experimental Medicine, 2012, 209(9): 1519-1528.
[cited by applicant]
Walfish, A.E., et al., “Crohn Disease (Regional Enteritis; Granulomatou Ileitis; Granulomatous Ileocolitis),” Merck Manual Professional Version, 2020, pp. 1-7.
[cited by applicant]
Walfish, A.E., et al., “Overview of Inflammatory Bowel Disease,” Merck Manual Professional Version, 2020, pp. 1-3.
[cited by applicant]
Walfish, A.E., et al., “Ulcerative Colitis,” Merck Manual Professional Version, 2020, pp. 1-8.
[cited by applicant]
Wang, H. et al., “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,” Science, 1999, 285(5425): 248-251.
[cited by applicant]
Wang, L. et al., “Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture,” Experimental Hematology, 2002, 30: 831-836.
[cited by applicant]
Wang, H. et al., “Kansaibou no riron to gijutu,” Science Press, Mar. 2005, 5: 58-61 (English translation attached, titled “Theories and Technologies for Stem Cells”).
[cited by applicant]
Wang, H.L. et al., “High mobility group protein B1 and the research progress of its biological effect,” Journal of Chinese Modern Surgery, 2006, 3(22): 1806-1809 (English translation attached).
[cited by applicant]
Wang, H. Y., et al., “Rate of Evolution in Brain-Expressed Genes in Humans and Other Primates.” PLoS Biol., 2007, 5(2): e13.
[cited by applicant]
Wang, Y., “Biology of hematopoietic stem cell and the research method therof,” Science Press, Mar. 2007, 1st Edition, pp. 56-58.
[cited by applicant]
Wang, W. et al., “Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model,” Regen Med, Mar. 2011, 6(2): 179-190.
[cited by applicant]
Wang, F.-C., et al., “Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro.” World J Gastroenterol, Jul. 7, 2015, 21(25): 7764-7776.
[cited by applicant]
Watanabe, T., et al., “The Role of HMGB-1 on the Development of Necrosis During Hepatic Ischemia and Hepatic Ischemia/Reperfusion Injury in Mice.” Journal of Surgical Research, 2005, 124: 59-66.
[cited by applicant]
Weintraub, R. G., et al. “Dilated cardiomyopathy.” The Lancet 390.10092 (2017): 400-414.
[cited by applicant]
Wexler, S. et al., “Adult Bone Marrow is a Rich Source of Human Mesenchymal ‘Stem’ Cells but Umbilical Cord and Mobilized Adult Blood are Not,” British Journal of Haematology, 2003, 121(2): 368-374.
[cited by applicant]
Whisstock, J. C., et al., “Prediction of Protein Function from Protein Sequence and Structure.” Quarterly Reviews of Biophysics, 2003, 36(3): 307-340.
[cited by applicant]
Wilgus, T. A., et al. “Neutrophils and wound repair: positive actions and negative reactions.” Advances in wound care 2.7 (2013): 379-388.
[cited by applicant]
Witkowski, A., et al., “Conversion of a B-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine.” Biochemistry, 1999, 38: 11643-11650.
[cited by applicant]
Wolf, G. et al., “From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease,” Diabetes, Jun. 2005, 54(6): 1626-1634.
[cited by applicant]
Woodbury, D. et al., “Adult Rat and Human Bone Marrow Stromal Cells Differentiate into Neurons,” Journal of Neuroscience Research, Aug. 15, 2000, 61(4): 364-370.
[cited by applicant]
Wu, Y. et al., “Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and Angiogenesis,” Stem Cells, 2007, 25(10): 2648-2659. Epub Jul. 5, 2007.
[cited by applicant]
Yamada, T. et al., “Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells,” Blood, Mar. 2003, 101(6): 2227-2234.
[cited by applicant]
Yamaoka, S., et al., “1043 Systemic delivery of HMGB1 peptide ameliorates imiquimod-induced psoriasis-like dermatitis.” Journal of Investigative Dermatology, 2018, 138(5): S177.
[cited by applicant]
Yang, D. et al., “High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin,” Journal of Leukocyte Biology, 2007, 81(1): 59-66. Epub Sep. 11, 2006.
[cited by applicant]
Yang, H., et al., “Reversing established sepsis with antagonists of endogenous high-mobility group box 1.” Proceedings of the National Academy of Sciences, 2004, 101(1): 296-301.
[cited by applicant]
Yang, S., et al., “Does Pretreatment of Bone Marrow Mesenchymal Stem Cells with 5-Azacytidine or Double Intravenous Infusion Improve Their Therapeutic Potential for Dilated Cardiomyopathy?” Medical Science Monitor Basic…
[cited by applicant]
YBOX1_Human, Accession No. P67809, accessed Nov. 10, 2021.
[cited by applicant]
Youn, J.H. et al., “High Mobility Group Box 1 Protein Binding to Lipopolysaccharide Facilitates Transfer of Lipopolysaccharide to CD14 and Enhances Lipoplysaccharide-Mediated TNF-α Production in Human Monocytes,” Journa…
[cited by applicant]
Yu, Q., et al., “Impact of Repeated Intravenous Bone Marrow Mesenchymal Stem Cells Infusion on Myocardial Collagen Network Remodeling in a Rat Model of Doxorubicin-Induced Dilated Cardiomyopathy.” Molecular and Cellular…
[cited by applicant]
Yuan, Y. et al., “Differentiation of Mesenchymal Stem Cells in Cardiomyogenic Cells Under the Induction of Myocardial Cell Lysate,” Chinese Journal of Cardiology, 2005, 33(2): 170-173.
[cited by applicant]
Zheng, X., et al., “Adeno-associated virus-mediated colonic secretory expression of HMGB1 A box attentuates experimental colitis in mice.” J Gene Med, 2016, 18(10): 261-272.
[cited by applicant]
Zhou, X. et al., “Exogenous High-Mobility Group Box 1 Protein Injection Improves Cardiac Function after Myocardial Infarction: Involvement of Wnt Signaling Activation,” Journal of Biomedicine and Biotechnology, 2012, vo…
[cited by applicant]
Zhou, X., et al., “Section 2 The translation process of genetic information.” Molecular Genetics, 1992, pp. 141-143.
[cited by applicant]
Zhou, Y.-H., et al., “High mobility group box 1 protein attenuates myocardial ischemia reperfusion injury via inhibition of the p38 mitogen-activated protein kinase signaling pathway.” Experimental and Therapeutic Medic…
[cited by applicant]
Gueukdjian S.A., “Intra-Arterial Injections in the Treatment of Peripheral Vascular Disease,” Postgrad Medical Journal, Jan. 1955, 31(351): 30-31.
[cited by applicant]
Guillot, L., et al., “Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways.” Journal of Biological Chemistry, Jan. 2004, 279(4): 2712-2718.
[cited by applicant]
Guo, J., et al., “Monocyte Chemotactic Protein-1 Promotes the Myocardial Homing of Mesenchymal Stem Cells in Dilated Cardiomyopathy.” International Journal of Molecular Sciences, 2013, 14: 8164-8178.
[cited by applicant]
Harris, H.E., et al., “Alarmin(g) news about danger,” EMBO Reports, 2006, 7(8): 774-778.
[cited by applicant]
Harrison, C.A., et al., “Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8.” J. Biol. Chem., 1999, 274(13): 8561-8569.
[cited by applicant]
Healthwise Staff, “Age-related Macular Degeneration,” University of Michigan Health System, Aug. 2015, https:www.uofmhealth.org/health-library/hw176039.
[cited by applicant]
He, Y.T., et al., “HMGB1 Ameliorates Inflammatory Bowel Disease by Inducing Circulating Mesenchymal Stem Cells.” The 17th Congress of the Japanese Society for Regenerative Medicine, 2018, 34, Abstract.
[cited by applicant]
Heil, M. et al., “An engineered heparin-binding form of VEGF-E (hbVEGF-E),” Angiogenesis, 2003, 6(3): 201-211.
[cited by applicant]
Herrera, M.B. et al., “Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury,” Kidney International, 2007, 72: 430-441.
[cited by applicant]
Hiratsuka S. et al., “Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis,” Natural Cell Biology, Dec. 2006, 8(12): 1369-1375.
[cited by applicant]
Himgbiotech, “BoxA from HMGB1, human & mouse, LPS-free.” HMGBiotech Srl, 2008, C.F. e P.IVA 04942740962, http://www.hmgbiotech.com/products.php?ID=91, ,accessed Jan. 27, 2017 from internet>.
[cited by applicant]
HMGBiotech, “BoxA from HMGB1, human & mouse, LPS-free-Datasheet.” HMGBiotech Srl, 2008, Via Moretto da Brescia 25, 20133—Milano, Italy, http://www.hmgbiotech.com/upload/documenti/0515122144_boxa.
[cited by applicant]
“HNRPK_Human”, NCBI_TaxID=9606, Accession No. P61978, Jun. 2004.
[cited by applicant]
Hori, O. et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin,” Journal of Biological Chemistry, 1995, 270(43): 25752-25761.
[cited by applicant]
Hornef, M.W., et al., “Toll-like Receptor 4 Resides in the Golgi Apparatus and Colocalizes with Internalized Lipopolysaccharide in Intestinal Epithelial Cells.” J. Exp. Med., 2002, 195(5): 559-570.
[cited by applicant]
Hruby, V.J., “Designing Peptide Receptor Agonists and Antagonists.” Nature Reviews Drug Discovery, 2002, 1: 847-858.
[cited by applicant]
Hu, Z., et al. “Role of high-mobility group box 1 protein in inflammatory bowel disease.” Inflammation Research 64.8(2015): 557-563.
[cited by applicant]
Huttunen, H.J. et al., “Receptor for Advanced Glycation End Products-binding COOH-terminal Motif of Amphoterin Inhibits Invasive Migration and Metastasis,” Cancer Research, 2002, 62: 4805-4811.
[cited by applicant]
Ichinose, K., et al., “Antiangiogenic Endostatin Peptide Ameliorates Renal Alterations in the Early Stage of a Type 1 Diabetic Nephropathy Model.” Diabetes, Oct. 2005, 54(10): 2891-2903.
[cited by applicant]
Instruction Manual of HiTrap chelating HP (Amersham Biosciences), 2003, pp. 1-6.
[cited by applicant]
Ishikane, S., “Therapeutic application of allogenic fetal membrane-derived mesenchymal stem cells transplantation in regenerative medicine,” Pharmaceutical Bulletin of Fukuoka University, Mar. 2011, 11(0): 17-25.
[cited by applicant]
Ishikane, Shin, et al., “Development of multi-growth factor secreted fetal membrane-derived mesenchymal stem cell sheets.” Grants-in-Aid for Scientific Research, 2014, pp. 1-6.
[cited by applicant]
Jansen, J. et al., “Transplantation of hematopoietic stem cells from the peripheral blood,” Journal of Cellular and Molecular Medicine, 2005, 9(1): 37-50.
[cited by applicant]
Jayaraman, L. et al., “High mobility group protein-1 (HMG-1) is a unique activator of p53,” Genes & Development, 1998, 12(4): 462-472.
[cited by applicant]
Jiang, Y. et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, 2002, 418(6893): 41-49.
[cited by applicant]
Jiao, C. et al., “Researchers find nerve damage may precede diabetic retinopathy,” EurekAlert! Science News, Apr. 2016, https://www.eurekalert.org/pub_releases/2016-04/uoih-rfv042616.php.
[cited by applicant]
Jin, Y., “Isolating culture and induced differentiation of marrow mesenchyma stem cells,” Principles and Protocols of Tissue Engineering, Jun. 2004, 277-278 (English translation attached).
[cited by applicant]
Kaneda, et al., “Tissue repair mechanism by bone-marrow-derived stem cells.” Experimental Mediciner, 2013, 31(5): 655-661.
[cited by applicant]
Kassis, I. et al., “Isolation of mesenchymal stem cells from G-CSF mobilized human peripheral blood using fibrin microbeads,” Bone Marrow Transplantation, 2006, 37(10): 967-976.
[cited by applicant]
Kawabata, H. et al., “High Mobility Group Box 1 Is Upregulated After Spinal Cord Injury and Is Associated With Neuronal Cell Apoptosis,” Spine, 2010, 35(11): 1109-1115.
[cited by applicant]
Kern, S. et al., “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue,” Stem Cells, 2006, 24(5): 1294-1301.
[cited by applicant]
Kessler, M.W. et al., “Tissue Engineering and Cartilage,” Organogenesis, Jan. 2008, 4(1): 28-32.
[cited by applicant]
Kido, T., et al., “Abstract 15756: The Administration of High-morbidity Group Box 1 Fragment Prevents Deterioration of Cardiac Performance by Enhancement of Bone-marrow Mesenchymal Stem Cells Homing in the Delta-sarcogl…
[cited by applicant]
Kikuchi, K. et al., “HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review),” Experimental and Therapeutic Medicine, 2011, 2: 767-770.
[cited by applicant]
Kikuchi, K. et al., “Systemic administration of HMGB1 improves bleomycin-induced skin fibrosis by locally accumulating bone marrow mesenchymal stem cells.” Regenerative Medicine, Feb. 1, 2017, 16: 422.
[cited by applicant]
Kim, S. et al., “Skin Regeneration Using Keratinocytes and Dermal Fibroblasts Cultured on Biodegradable Microspherical Polymer Scaffolds,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2005, 75(…
[cited by applicant]
Kirov, S.A. et al., “In Vivo 2-Photon Microscopy Reveals G-CSF Enhanced Mobilization and Targeting of Neo-Endogenous Bone Marrow Stromal Cells to Stroke Injury Sites,” Stroke, Apr. 2009, 40(4): 1-2, e133, Abstract No. 1…
[cited by applicant]
Kitahara, T. et al., “High-Mobility Group Box 1 Restores Cardiac Function After Myocardial Infarcation in Transgenic Mice,” Cardiovascular Research, European Society of Cardiology, Oct. 1, 2008, 80: 40-46.
[cited by applicant]
Koc, O. et al., “Mesenchymal Stem Cells: Heading into the Clinic,” Bone Marrow Transplantation, 2001, 27(3): 235-239.
[cited by applicant]
Kohno, T. et al., “High Mobility Group Box 1 Protein is Associated With Post-Infarction Healing Process and Left Ventricular Remodeling,” Circ. J., 2008, 72, Supplement 1, P J-004: 510-511.
[cited by applicant]
Kokkola, R., et al., “Rage is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages.” Scandinavian Journal of Immunology, 2005, 61: 1-9.
[cited by applicant]
Komurasaki, Y., et al., “555 Systemic HMGB1 Administration Ameliorated Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Bone Marrow-Derived Mesenchymal Stem Cells to the Lesion.” Journal of Investigative Der…
[cited by applicant]
Komurasaki, Y., et al., “HMGB1 Ameliorates Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Mesenchymal Stem Cells to the Lesion.” The 48th Annual Meeting of the Japanese Society of Matrix Biology and Medici…
[cited by applicant]
Koren-Morag, N., et al., “White Blood Cell Count and the Incidence of Ischemic Stroke in Coronary Heart Disease Patients.” The American Journal of Medicine, 2005, 118: 1004-1009.
[cited by applicant]
Laflamme, M. et al., “Regenerating the heart,” Nature Biotechnology, Jul. 2005, 23(7): 845-856.
[cited by applicant]
Lanza, R. et al., “Essentials of Stem Cell Biology—Chapter 27, Mesenchymal Stem Cells,” Elsevier Academic Press, 2006, pp. 205-210.
[cited by applicant]
La Rosa, T.J. et al., “Glycine max protein SEQ ID No. 211221,” Geneseq Accession No. AFQ20044, 2007.
[cited by applicant]
Lemp, M.A., et al., “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007).” The Ocular Surface, Apr. 2007, 5(2): 75-…
[cited by applicant]
Liao, D., et al. “Vascular smooth cell proliferation in perfusion cluture of porcine carotid arteries.” Biochemical and biophysical research communications 372.4 (2008): 668-673.
[cited by applicant]
Li, S. et al., “Millennium Review, Nonviral gene therapy: promises and challenges,” Gene Ther., 2000, 7: 31-34.
[cited by applicant]
Ahrens, N., et al. “Mesenchymal Stem Cell Content of Human Vertebral Bone Marrow.” Transplantation 78(6): 925-929, (Year: 2004).
[cited by applicant]
Aikawa, E., et al. “HMGB1 accelerates skin regeneration by inducing bone marrow mesenchymal stromal cells.” Journal of Dermatological Science 84(1): 1-14, (Year: 2016).
[cited by applicant]
Alshorafa, A. K., et al. “Psoriasis is associated with low serum levels of hydrogen sulfide, a potential anti-inflammatory molecule.” The Tohoku Journal of Experimental Medicine 228.4 (2012): 325-332.
[cited by applicant]
Andersson, U. et al. “HMGB1 is a Therapeutic Target for Sterile Inflammation and Infection.” Annu Rev Immunol. 29: 139-162 (Year: 2011).
[cited by applicant]
Andrassy, M., et al. “High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart.” Circulation 117(25): 3216-3226, (Year: 2008).
[cited by applicant]
Baer, P. C. et al. “Comprehensive Phenotypic Characterization of Human Adipose-Derived Stromal/Stem Cells and Their Subsets by a High Throughput Technology.” Stem Cells and Development 00(00):1-10, (Year: 2012).
[cited by applicant]
Bhattacharya, R. et al. “Impact of genetic variation on three dimensional structure and function of proteins.” PloS one, 12(3): 1-22, Mar. 15, 2017.
[cited by applicant]
Bigazzi, P. E., et al. “Introduction to Review Series on Animal Models of Human Disease.” Clinical Immunology and Immunopathology, 74(1): 1, (Year: 1995).
[cited by applicant]
Bretag, A. “Too much hype, not enough hope: Are balanced reporting and proper controls too much to expect from therapeutic studies in animal models of neuromuscular diseases that presage clinical trials in humans?” Neur…
[cited by applicant]
Charles River Laboratories Ineternational, Inc., Research Models, C57BL/6 Mice, Nomenclature: C57BL/6NCrl, 2019. Retrieved from: https://www.criver.com/sites/default/files/resources/doc_a/C57BL6MouseModelInformationShee…
[cited by applicant]
Del Buono, M. G., et al. “Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction.” Current Cardiology Reports, 24(10): 1505-1515, Aug. 16, 2022.
[cited by applicant]
Fenton, A. W. et al. “Rheostat positions: a new classification of protein positions relevant to pharmacogenomics.” Medicinal Chemistry Research 29:1133-1146, (Year: 2020).
[cited by applicant]
Freitag, J., et al. “The effect of autologous adipose derived mesenchymal stem cell therapy in the treatment of a large osteochondral defect of the knee following unsuccessful surgical intervention of osteochondritis di…
[cited by applicant]
Funayama, A., et al. “Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure.” Cardiovascular Research 99(4): 657-664, (Year: 2013).
[cited by applicant]
Goodman, W. A., et al. “IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.” The Journal of Immunology 183.5 (2009): 3170-3176.
[cited by applicant]
Grossman, R. M., et al. “Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.” Proceedings of the National Academy of Sciences 86.16 (1989): 6367-6371.
[cited by applicant]
Guo, H. H., et al. “Protein tolerance to random amino acid change.” Proceedings of the National Academy of Sciences 101(25):9205-9210, Jun. 22, 2004.
[cited by applicant]
He, Y., et al. “Exogenous High-Mobility Group Box 1 Protein Prevents Postinfarction Adverse Myocardial Remodeling Through TGF-β/Smad Signaling Pathway.” Journal of Cellular Biochemistry 114: 1634-1641, (Year: 2013).
[cited by applicant]
Hinderer, S., et al. “Cardiac fibrosis—A short review of causes and therapeutic strategies.” Advanced drug delivery reviews 146 (2019): 77-82.
[cited by applicant]
Justice, M. J., et al. “Using the mouse to model human disease: increasing validity and reproducibility.” Dis Model Mech. 9(2):101-103, Feb. 1, 2016.
[cited by applicant]
Kaneko, M., et al. “Abstract 11250: Bone Marrow Mononuclear Cell Transplantation Improves Cardiac Function in Ischemic Cardiomyopathy via High Mobility Group Box 1 Released from Dead Donor Cells.” Circulation 126:A11250…
[cited by applicant]
Kwak, M. S., et al. “Immunological significance of HMGB1 post-translational modification and redox biology.” Frontiers in immunology 11 (2020): 1-16.
[cited by applicant]
Lee, S.-A., et al. “The role of high mobility group box 1 in innate immunity.” Yonsei medical journal 55.5 (2014): 1165-1176.
[cited by applicant]
Lee, G., et al. “Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to Galert.” Proceedings of the National Academy of Sciences, 115(19): E4463-E4472, Apr. 19, 2018.
[cited by applicant]
Li, D. C. J. “Research progress on the mechanism and induction methods for the differentiation of mesenchymal stem cells.” Infect Inflamm Rep, vol. 12, No. 1, Mar. 2011: 62-64.
[cited by applicant]
Lotze, M., et al. “High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.” Nature Reviews Immunology 5(4):331-342, (Year: 2005).
[cited by applicant]
Morikawa, S., et al. “Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in urine bone marrow.” The Journal of Experimental Medicine 206(11):2483-2496, (Year: 2009).
[cited by applicant]
Narumi, T., et al. “Abstract 15265: Cardiac-specific Overexpression of High-Mobility Group Box 1 Protects Cardiomyocyte from Apoptosis During the Pathogenesis of Doxorubicin Cardiomyopathy.” Circulation, 126:A15265, Mar…
[cited by applicant]
Neuner, P., et al. “Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis.” Journal of Investigative Dermatology 97.1 (1991): 27-33.
[cited by applicant]
Nojiri, S., et al. “Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.” Inflammation and Regeneration 41(28):1-15, (Year: 2021).
[cited by applicant]
Paola, R. D., et al. “S-acetyl-glutathione attenuates carbon tetrachloride-induced liver injury by modulating oxidative imbalance and inflammation.” International journal of molecular sciences 23.8 (2022): 4429.
[cited by applicant]
PROCR gene—Protein C Receptor. Downloaded from https://www.genecards.org/cgi-bin/carddisp.pl?gene=PROCR, accessed Mar. 31, 2023.
[cited by applicant]
Scholten, D., et al. “The carbon tetrachloride model in mice.” Laboratory animals 49.1_suppl (2015): 4-11.
[cited by applicant]
Shedoeva, A., et al. “Wound healing and the use of medicinal plants.” Evidence-Based Complementary and Alternative Medicine: 1-31 (2019).
[cited by applicant]
Sidney, L. E. “Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors.” Stem Cells 32(6): 1380-1389, Feb. 4, 2014.
[cited by applicant]
Sisakian, H. S. et al. “Dilated Cardiomyopathy: Evoltion of Pathogenesis Concepts and Potential for New Therapies.” New Armenian Medical Journal 9(1):4-18, (Year: 2015).
[cited by applicant]
Suchacki, K. J. “Bone marrow adipose tissue: formation, function and regulation.” Current opinion in Pharmacology 28:50-56, (Year: 2016).
[cited by applicant]
Tamai, K. et al. U.S. Appl. No. 18/152,249, “Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues.” filed Jan. 10, 2023.
[cited by applicant]
Tamai, K. et al. “179 Systemic administration of HMGB1 peptide drastically improves survival of the RDEB model mice by mobilizing multipotent stem/progenitor cells from bone marrow”, Journal of Investigative Dermatology…
[cited by applicant]
Taniguchi, N. et al. “Stage-Specific Secretion of HMGB1 in Cartilage Regulates Endochondral Ossification.” Molecular and Cellular Biology, 27(16):5650-5664, (Year:2007).
[cited by applicant]
WHO Drug Information, vol. 32, No. 1, Appendix 5, p. 155, (Year: 2018).
[cited by applicant]
Wynn, T. A., et al. “Mechanisms of fibrosis: therapeutic translation for fibrotic disease.” Nat Med. 18(7): 1028-1040, (Year: 2013).
[cited by applicant]
Yang, H. et al. “The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.” J. Leukoc Biol. 93(6): 865-873, (Year: 2013).
[cited by applicant]
Yang, Y.-H. K., et al. “Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro.” Stem cell research & therapy 9 (2018): 1-14.
[cited by applicant]
Younis, S., et al. “Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker.” The Journal of Rheumatology 39.10 (2012): 2055-2056.
[cited by applicant]
Zandarashvili, L., et al. “Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy.” Journal of Biological Chemistry 288.17 (2013): 11621-116…
[cited by applicant]
Zhao, J., et al. “The Study Progression of the Role of HMGBI in Ichemic Heart Failure.” Molecular Cardiology of China, pp. 1169-1171, Dec. 25, 2014.
[cited by applicant]
Pittenger, M. et al., “Multilineage Potential of Adult Human Mesenchymal Stem Cells,” Science, 1999, 284(5411): 143-147.
[cited by applicant]
NPM_Human, Accession No. P06748, Jan. 1988.
[cited by applicant]
Popovic, K. et al., “Increased Expression of the Novel Proinflammatory Cytokine High Mobility Group Box Chromosomal Protein 1 in Skin Lesions of Patients With Lupus Erythematosus,” Arthritis & Rheumatism, 2005, 52(11): …
[cited by applicant]
PRS6A_Human, Accession No. P17980, Nov. 1990.
[cited by applicant]
Pusterla, T. et al., “High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1,” Autoimmunity, 2009, 42(4): 308-310.
[cited by applicant]